January 30, 2018 08:17 AM EST

Pfizer sweeps out a lineup of neuroscience drugs — as well as cancer and NASH programs — into the scrap heap

John Carroll

Editor & Founder

Anyone shopping for some early- and mid-stage neurosciences programs should look over the menu of discontinued programs out from Pfizer $PFE this morning. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Pfizer sweeps out a lineup of neuroscience drugs — as well as cancer and NASH programs — into the scrap heap

John Carroll

Editor & Founder

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

The election is Tuesday. What’s at stake for the pharma industry?

FDA cites Mark Cuban's drug compounding center in Dallas with sterility, quality concerns

Rare disease biopharma companies weigh in on FDA's new innovation hub

'We play to win': AstraZeneca details first results for oral GLP-1 and broader obesity ambitions

Is there room for MASH drugs in a GLP-1 world?

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

Pfiz­er sweeps out a line­up of neu­ro­science drugs — as well as can­cer and NASH pro­grams — in­to the scrap heap

Editor & Founder

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Pfizer sweeps out a lineup of neuroscience drugs — as well as cancer and NASH programs — into the scrap heap